Establishment of a human fusion partner for making human T-T hybridomas which can grow in serum free medium.
A new human fusion partner, ICLU-T was established for making human T-T hybridomas. Some 6-thioguanine resistant (6-TGr) clones were separated from human T cell acute lymphocytic leukemia, PEER. The fastest growing clone of the 6-TGr cells was scaled up and was cultured in serum free medium. The clone that proliferated most quickly in the serum free medium was separated and named ICLU-T. When ICLU-T was fused with human peripheral blood lymphocytes by using only polyethylene glycol, the viability of fused cells was below 20% just after fusion and the fusion efficiency was 0.01-0.02 per 10(5) parent cells. Whereas, the combined use of 1% lecithin with polyethylene glycol increased the viability over 50% and the fusion efficiencies over 0.2 per 10(5) parent cells on the average. In a total of 34 clones of obtained hybridomas, there were 25 CD2 positive clones. CD4 positive or CD8 positive clones of the CD2 positive clones were 12 and 5 clones, respectively. Further, 4 clones of all hybridomas were CD19 positive, and one clone of these hybridomas was an Ig producer. These obtained hybridomas could proliferate in serum free medium.
National Research Institute of Vegetables, Ornamental Plants and Tea, Shizuoka, Japan.
H
H
Kawahara
M
M
Maeda-Yamamoto
K
K
Hakamata
D002455:Cell Division; D002459:Cell Fusion; D002460:Cell Line; D016895:Culture Media, Serum-Free; D006801:Humans; D006825:Hybridomas / Q000502:physiology*; D010713:Phosphatidylcholines / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000494:pharmacology; D013601:T-Lymphocytes / Q000502:physiology*
D016895:Culture Media, Serum-Free; D010713:Phosphatidylcholines; D011092:Polyethylene Glycols